Introduction

intracranial aneurysms and subarachnoid hemorrhage
Subarachnoid hemorrhage (SAH) is a common and frequently life-threatening cerebrovascular disease that usually occurs at a relatively young age and has an unpredictable onset; in fact, the average age is about 50 years old [1, 2] .
It is a devastating condition in which arterial bleeds into the subarachnoid space damaging brain perfusion and function [3] . Although it accounts for only 5% of strokes, its high rates of mortality and disability greatly increase the burden of society and families [4] . Indeed, the mortality rate of SAH ranges from 8.3% to 66.7% [5] . Additionally, the surviving patients suffer neurological injuries that seriously affect the quality of life to the point that productive patients are unable to return to work and likely needing constant care by others [6] . To date, AHA/ASA experts have consensus on the definition that stroke caused by subarachnoid hemorrhage only includes spontaneous SAH, which is mostly related with a ruptured intracranial aneurysm [1, 2, 7, 8] .
The conventional secondary complications of SAH include rebleeding, early brain injury, cerebral vasospasm, delayed cerebral ischemia and chronic hydrocephalus [6, [9] [10] [11] . Following SAH, non neurological complications are also present; in fact, SAH patients are vulnerable to multiple extracerebral organ dysfunctions, such as neurocardiogenic injury, neurogenic pulmonary injury, neurogenic renal injury, hyperglycemia, electrolyte imbalance and hematological failure [12] . Despite early surgical and endovascular treatment of ruptured aneurysms has been improved greatly, the clinical outcome remains disappointing and leave SAH still a serious health problem. It leaves patients with psychological and physical damage, and also financial loss [6, 13] . Thus, the pathogenesis and treatment of intracranial aneurysms and SAH need further investigation, in order to better understand this disease and reduce related incidence, morbidity and mortality. This review summarises the noncoding RNAs studies in intracranial aneurysm and SAH. 
siRNAs
RNA interference (RNAi) technology to silence gene was first described in Caenorhabditis Elegans and expanded to plants, Drosophila and fungi. It is processed into short RNA fragments with approximately 21 bp by an RNase type-III enzyme-Dicer. Subsequently, the specific RNA fragments activate an RNAinduced silencing complex (RISC) and degrade complementary mRNA with one strand retrained, after which it is recycled for several rounds [21] . Recently, RNAi-mediated gene depletion in a sequence-specific manner has gained increasingly popularity in mammalian cells by synthetic dsRNA, known as siRNA [22] . This strategy has been used successfully in various cancers and many other diseases, such as autoimmune, dominant genetic and nervous system disorders [23] . Thus, siRNAs offer a new therapeutical strategy for the future control and treatment of diseases.
lncRNAs
Another great achievement of the past decade has been the discovery of lncRNAs. lncRNAs are defined as transcripts greater than 200 bp in length. They are similar to protein coding transcripts in many ways; as in processing steps, histone-modification profiles, splicing signals and exon/intron lengths, however they lack of significant coding sequences [24] . lncRNAs are quite heterogeneous in several aspects, such as genomic context, size, life cycles and mechanisms of regulation. They may be standalone transcription units or transcribed from antisense to other genes with different degrees of overlap from enhancers, promoters, introns of other genes or pseudogenes [25] . Indeed, lncRNAs can be divided into five biotypes according to their proximity to proteincoding genes:sense, antisense, bidirectional, intronic and intergenic [26, 27] . Increasing evidence indicated that lncRNAs play a crucial role in various biological and pathological processes, such as neural differentiation, cell fate decisions, synaptic plasticity, behavior and neuroprotection [25, 28] . Indeed, a number of lncRNAs contribute to central nervous system disorders, including stroke, neuro-immunological, neuro-developmental, neuro-degenerative, neuro-oncological and psychiatric diseases [29, 30] .
ncRNAs in intracranial aneurysms and subarachnoid hemorrhage
In recent years, increasing studies have focused on non-coding RNAs as regulators of post-transcriptional gene expression and in response to SAH.
miRNAs
It is well known that miRNAs have served as novel biomarkers and crucial regulators of pathological mechanisms for vascular diseases [31] . and their alteration exhibited consistency with the microarray assay analysis [41] . In line with the above report [39] , miR-29b and miR-133 were also showed to be dysregulated in intracranial aneurysms in this study. Furthermore, ruptured saccular intracranial aneurysms in SAH patients were also studied by Chen et al. This study revealed that miR-661, miR-1207-5p and miR-1915-3p were predicted to be activated, while miR-33a-5p, miR-659-3p and miR-524-5p were predicted to be inactivated using Sylamer method [42] . Among these results, miR-524-5p, a brain-specific miRNA, suppressed cell proliferation and invasion by directly targeting Jagged-1 and Hes-1 [43] .
Some above screened miRNAs were used for bioinformatics and functional analysis.
Jin H et al., employed TargetScan Human to predict target genes and Gene Ontology (GO)
analysis to identify functional classification of target genes. 9 target genes were found to be associated with the pathogenesis of aneurysms, such as TRIB1, SSX3, ARFIP2, BCL6B, EP300, EDN1, CHAF1A, PDCD6 and FMN2 [36] . In this latest report integrated database Because the microarray results show greater variation compared to RT-qPCR data, [44] , here, we summarised RT-qPCR confirmed miRNA information to date (Table 2) . Moreover, the screened dysregulated miRNAs together with their target genes and functional analysis are listed in Table 3 . Has-let-7a Plasma and IAs Programmed cell death, Response to oxidative stress, Smooth muscle cell proliferation [37] , [41] hsa-mir-133 IAs Modulate SMC proliferation, maintain the skeletal muscle homeostasis [39] , [41] hsa-mir-29b IAs Manipulated aneurysm formation, progression and rupture rate [39] , [41] hsa-mir-25 Serum and plasma serve as potential biomarkers in intracranial aneurysms [36] , [37] hsa-miR-223 Serum and rabbit Associated with vascular remodeling, inflam mation and homeostasis [35] , [36] in both hemispheres, such as ameliorated sensorimotor deficits. Thus, the P2X7R/ 
lncRNAs
In total, 64 upregulated lncRNAs and 144 downregulated lncRNAs were detected by microarray hybridisation in the brain of adult male wistar rats following SAH. Of note, the lncRNA MRAK038897, with the most obvious alternation, was involved in ankyrin repeat and suppressor of cytokines signaling box 3, which was found to regulate the neuronal inflammatory process of EBI. Thus, it was considered that lncRNA MRAK038897 might play a critical role in the regulation of EBI [63] . kb from CDKN2A, with the lncRNA ANRIL also lied within this interval [64] . Coincidentally, the robust association of the SNP rs1333040
with intracranial aneurysms was also found by meta-analysis [65] . Furthermore, genome-wide association studies (GWAS)
had surprisingly identified lncRNA ANRIL (NR_003529, in chromosome 9p21; also called CDKN2BAS) as a genetic susceptibility locus related with intracranial aneurysms [66, 67] .
Of note, in the specific lncRNA ANRIL, foroud T provided evidence that a SNP (CDKN2BAS; rs6475606) was associated with intracranial aneurysms [68] . Moreover, previous studies reported many other SNPs in this region were also related with intracranial aneurysms.
The SNP, rs10757278 (Allele G), was the first common sequence variant that confers rapid progression risk of intracranial aneurysms in European individuals [69] . Another two SNPs, rs10757278 (Allele G) and rs1333045
(Allele A) were demonstrated to have extraordinary associations with intracranial aneurysms. Additionally, the association of rs10757278 (Allele G) remained significant after adjustment for hypertension as well as smoking, while rs1333045 (allele A) did not.
Altogether, approximately 24% of the samples were homozygous for the rs10757278 G allele,in line with previous studies [69, 70] .
Concluding remarks and perspective
As and development, and may be used as novel biological markers to predict the occurrence of intracranial aneurysms rupture [36] . In intracranial aneurysms, miR-29b and miR-133 were also showed dysregulated in both studies, confirming yet again that the changes of miRNA expression were repeatable [39, 41] . 
